Advaxis, Inc. (OTCMKTS:ADXS) Sees Significant Decline in Short Interest
Advaxis, Inc. (OTCMKTS:ADXS) Sees Significant Decline in Short Interest
Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) was the target of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 2,400 shares, a decrease of 7.7% from the October 31st total of 2,600 shares. Based on an average daily trading volume, of 4,100 shares, the short-interest ratio is currently 0.6 days.
Advaxis,Inc.(場外交易代碼:ADXS-GET Rating)是空頭股數11月份大幅下降的目標。截至11月15日,空頭股數共有2400股,比10月31日的2600股減少了7.7%。以日均成交量4,100股計算,短息比目前為0.6天。
Advaxis Price Performance
Advaxis性價比
ADXS stock opened at $1.66 on Monday. Advaxis has a 12 month low of $1.02 and a 12 month high of $30.56. The firm has a 50 day simple moving average of $1.89 and a 200 day simple moving average of $2.49. The firm has a market cap of $3.01 million, a PE ratio of -16.55 and a beta of 2.07.
ADXS股票週一開盤報1.66美元。Advaxis的12個月低點為1.02美元,12個月高位為30.56美元。該公司的50日簡單移動均線切入位在1.89美元,200日簡單移動均線切入位在2.49美元。該公司市值為301萬美元,市盈率為-16.55,貝塔係數為2.07。
Advaxis (OTCMKTS:ADXS – Get Rating) last posted its earnings results on Monday, September 12th. The biotechnology company reported ($3.83) earnings per share for the quarter.
Advaxis(OTCMKTS:ADXS-GET Rating)最近一次公佈收益業績是在9月12日星期一。這家生物技術公司公佈了本季度每股收益(3.83美元)。
Analyst Ratings Changes
分析師評級發生變化
Advaxis Company Profile
Advaxis公司簡介
(Get Rating)
(獲取評級)
Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
Advaxis,Inc.是一家臨牀階段的生物技術公司,專注於在美國發現、開發和商業化專有的單核細胞增生性李斯特菌(LM)技術抗原遞送產品。該公司正在開發ADXS-PSA,這是用於治療轉移性前列腺癌的第二階段臨牀試驗;ADXS-503,用於治療非小細胞肺癌;以及ADXS-504,用於治療前列腺癌。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- Intel is a Sleeping Giant Ready to Awaken
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- 免費獲取StockNews.com關於Advaxis的研究報告(ADXS)
- 英特爾是一個沉睡的巨人,準備醒來
- 為什麼CSL有限公司的股票值得一看
- MarketBeat:回顧一週11/28-12/02
- Okta Inc.慶祝收益節節攀升,但他們能持續這種提振嗎?
- 機構正在購買安巴雷拉,你應該嗎?
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
接受Advaxis Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Advaxis和相關公司的最新新聞和分析師評級的每日簡要摘要。